Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108883
Filing Date
2025-08-14
Accepted
2025-08-14 16:14:51
Documents
127
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atai-20250630.htm   iXBRL 10-Q 4748946
2 EX-3.1 atai-ex3_1.htm EX-3.1 601095
3 EX-10.3 atai-ex10_3.htm EX-10.3 95367
4 EX-10.17 atai-ex10_17.htm EX-10.17 88567
5 EX-31.1 atai-ex31_1.htm EX-31.1 16051
6 EX-31.2 atai-ex31_2.htm EX-31.2 17415
7 EX-32.1 atai-ex32_1.htm EX-32.1 10171
8 EX-32.2 atai-ex32_2.htm EX-32.2 10028
9 GRAPHIC img79574739_0.jpg GRAPHIC 8836
10 GRAPHIC img107788630_0.jpg GRAPHIC 423001
11 GRAPHIC img195838379_0.jpg GRAPHIC 8836
  Complete submission text file 0000950170-25-108883.txt   23157658

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atai-20250630.xsd EX-101.SCH 3572411
130 EXTRACTED XBRL INSTANCE DOCUMENT atai-20250630_htm.xml XML 4349683
Mailing Address PROF. J.H. BAVINCKLAAN 7 AMSTELVEEN Netherlands 1183
Business Address PROF. J.H. BAVINCKLAAN 7 AMSTELVEEN Netherlands 1183 49 89 2153 9035
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40493 | Film No.: 251219241
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)